
    
      Aims of the study were :

        -  to assess the overall efficacy of rituximab in a cohort of unselected patients with
           hairy-cell leukemia

        -  to identify factors associated to treatment response, to duration of treatment response
           and to patient survival in a cohort of unselected patients with hairy-cell leukemia
    
  